biostudies-literatureUnknown43(7)Naveen RThe safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectivelyRheumatology international1265-1275https://www.ebi.ac.uk/biostudies/studies/S-EPMC10064600biostudies-literatureSystemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.PMC10064600Goswami RPDistler OVelikova TCampagne JFonseca JESainaghi PPDel Papa NJain AGheita TGromova MAChinoy HOrsolini GSebastiani MCOVAD Study GroupPatro PSVenerito VZuleta WGRDanielli MGPande ARShinjo SKParisi SMilchert MCansu DUKuwana MLilleker JBAjmani SCavagna LAggarwal RChowdhury ACLandon-Cardinal ODay JSalim BKimura NTomaras SSebastiani GDBommakanti KTPhatak SYoshida ASilva JAPMathew AJNagy-Vincze MPandya SCShenoy PKaneko YGupta VLimaye VGracia-Ramos AEMaurier FShaharir SSM MMHudson MSaha SSato SThakare DRAgarwal VChandwar KFabiola ALa Torre IGPilania RKFusaro ETehozol EAZGiannini MGonzalez RASharma AGupta LSerrano JRAharonov OGovoni MLangguth DChatterjee TKavadichanda CGDe Angelis RMakol ASen PNaveen RFranceschini FBocci EBQuartuccio LJagtap KTraboco LSNakashima RParodis IWibowo SAKMeyer ANune AZiade NSambataro GTan ALKnitza JHoff LSNeedham MJoshi MKardes SShukla AZimba OBarman BLoarce-Martos JHmamouchi IAsranna APrieto-Gonzalez SPauling JDWincup CSrivastav NSaavedra MANikiphorou ESingh YPRanjan RfalseSystemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively2023-01-01T00:00:00Z2023 Jul2025-04-04T11:59:29.347Z2025-02-19T04:00:49.55ZS-EPMC100646003700029510.1007/s00296-023-05310-9